Alzheimer Disease & Dementia

09.27.24

Results of the Clarity AD Trial Assessing Lecanemab Treatment for Early Alzheimer Disease

Lynn D. Kramer, MD, FAAN and Christopher van Dyck, MD

Lynn D. Kramer, MD, FAAN, Chief Clinical Officer, Deep Human Biology Learning at Eisai and a member of the Eisai Executive Committee, and Christopher van Dyck, MD, Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, provide an overview of key results from the Clarity AD clinical trial assessing the safety and efficacy of lecanemab in people with early Alzheimer disease presented at the 2024 Alzheimer's Association International Conference.